Association of ABCB1 and FLT3 polymorphisms with toxicities and survival in asian patients receiving sunitinib for renal cell carcinoma

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Chu, Ying Hsia ^a   Li, Huihua ^b   Tan, Hui Shan ^c   Koh, Valerie ^b   Lai, Johnathan ^a   Phyo, Wai Min ^a   Choudhury, Yukti ^a   Kanesvaran, Ravindran ^c   Chau, Noan Minh ^c   Toh, Chee Keong ^c   Ng, Quan Sing ^c   Tan, Puay Hoon ^b   Chowbay, Balram ^c,d,e   Tan, Min Han ^a,c  

^a INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d Singapore Health Services   (Singapore)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CD135 ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 1; SUNITINIB; TUMOR MARKER; VASCULOTROPIN RECEPTOR 2; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; FLT3 PROTEIN, HUMAN; INDOLE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; PYRROLE DERIVATIVE;

ABCB1 GENE; ABCG2 GENE; ADULT; ALLELE; ARTICLE; ASIAN; BIM GENE; CANCER SURVIVAL; CAUCASIAN; COMORBIDITY; CONTROLLED STUDY; DRUG SAFETY; ETHNICITY; FEMALE; FLT3 GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; HAND FOOT SYNDROME; HAPLOTYPE; HUMAN; KIDNEY CARCINOMA; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PREDICTION; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; VALIDATION PROCESS; VEGFR2 GENE; ADOLESCENT; ADVERSE DRUG REACTION; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; KIDNEY NEOPLASMS; METASTASIS; MIDDLE AGED; SINGAPORE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRROLES; SINGAPORE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942110373     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134102     Document Type: Article

References (40)

1. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship. Clinical Cancer Research. 2003; 9(1):327-37. PMID: 12538485
2. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368(9544):1329-38. Epub 2006/10/19. doi: 10.1016/s0140-6736(06)69446-4 PMID: 17046465.
3. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006; 24(1):25-35. Epub 2005/11/30. doi: 10.1200/jco.2005.02.2194 PMID: 16314617.
4. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2):115-24. Epub 2007/01/12. doi: 10.1056/NEJMoa065044 PMID: 17215529.
5. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine. 2013; 369(8):722-31. doi: 10.1056/NEJMoa1303989 PMID: 23964934.
6. Kim HS, Hong MH, Kim K, Shin SJ, Ahn JB, Jeung HC, et al. Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles. Oncology. 2011; 80(5-6):395-405. doi: 10.1159/000330361 PMID: 21829041
7. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA: the journal of the American Medical Association. 2006; 295 (21):2516-24. Epub 2006/06/08. doi: 10.1001/jama.295.21.2516 PMID: 16757724.
8. van der Veldt AAM, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. British journal of cancer. 2008; 99(2):259-65. doi: 10.1038/sj.bjc.6604456 PMID: 18594533
9. Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-Analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 2009; 15(7):2497-506. Epub 2009/03/05. doi: 10.1158/1078-0432.ccr-08-1893 PMID: 19258444.
10. Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, et al. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib-A multicentric retrospective analysis. Acta oncologica (Stockholm, Sweden). 2014; 53 (1):103-12. Epub 2013/02/21. doi: 10.3109/0284186x.2013.770600 PMID: 23421954.
11. van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol. 2009; 27 (26):4406-12. Epub 2009/08/12. doi: 10.1200/jco.2008.21.7679 PMID: 19667267.
12. Maeng CH, Yi JH, Lee J, Hong JY, Choi MK, Jung HA, et al. Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib. Anticancer research. 2013; 33 (10):4619-26. Epub 2013/10/15. PMID: 24123039.
13. Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, et al. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. British journal of cancer. 2013; 108(4):887-900. Epub 2013/03/07. doi: 10.1038/bjc.2012.548 PMID: 23462807; PubMed Central PMCID: PMCPMC3590652.
14. Scartozzi M, Bianconi M, Faloppi L, Loretelli C, Bittoni A, Del Prete M, et al. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. British journal of cancer. 2013; 108(5):1126-32. Epub 2013/03/21. doi: 10.1038/bjc.2012.501 PMID: 23511629; PubMed Central PMCID: PMCPMC3619056.
15. Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, Wirka R, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer. 2012; 118(7):1946-54. Epub 2011/09/02. doi: 10.1002/cncr.26491 PMID: 21882181.
16. Rutkowski P, Bylina E, Klimczak A, Switaj T, Falkowski S, Kroc J, et al. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure-one institution study. BMC Cancer. 2012; 12:107. Epub 2012/03/24. doi: 10.1186/1471-2407-12-107 PMID: 22439647; PubMed Central PMCID: PMC3361487.
17. Eechoute K, van der Veldt AA, Oosting S, Kappers MH, Wessels JA, Gelderblom H, et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clinical pharmacology and therapeutics. 2012; 92(4):503-10. Epub 2012/09/06. doi: 10.1038/clpt.2012.136 PMID: 22948895.
18. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, del Alba AG, Climent MA, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renalcell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011; 12(12):1143-50. Epub 2011/10/22. doi: 10.1016/s1470-2045(11)70266-2 PMID: 22015057.
19. van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, van Erp NP, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res. 2011; 17(3):620-9. Epub 2010/11/26. doi: 10.1158/1078-0432.ccr-10-1828 PMID: 21097692.
20. Kim HR, Park HS, Kwon WS, Lee JH, Tanigawara Y, Lim SM, et al. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer chemotherapy and pharmacology. 2013; 72(4):825-35. Epub 2013/09/10. doi: 10.1007/s00280-013-2258-y PMID: 24013576.
21. Beuselinck B, Lambrechts D, Van Brussel T, Wolter P, Cardinaels N, Joniau S, et al. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta oncologica (Stockholm, Sweden). 2014:1-10. Epub 2014/05/31. doi: 10.3109/0284186x.2014.918276 PMID: 24874929.
22. Salama NN, Yang Z, Bui T, Ho RJ. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci. 2006; 95(10):2293-308. Epub 2006/08/03. doi: 10.1002/jps.20717 PMID: 16883550.
23. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (New York, NY). 2007; 315 (5811):525-8. Epub 2006/12/23. doi: 10.1126/science.1135308 PMID: 17185560.
24. Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, et al. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. International journal of cancer Journal international du cancer. 2012; 130(1):223-33. Epub 2011/02/26. doi: 10.1002/ijc.26000 PMID: 21351087.
25. Diekstra MH, Klumpen HJ, Lolkema MP, Yu H, Kloth JS, Gelderblom H, et al. Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662. Clinical pharmacology and therapeutics. 2014. Epub 2014/02/26. doi: 10. 1038/clpt.2014.47 PMID: 24566734.
26. Singh O, Chan JY, Lin K, Heng CCT, Chowbay B. SLC22A1-ABCB1 Haplotype Profiles Predict Imatinib Pharmacokinetics in Asian Patients with Chronic Myeloid Leukemia. PLoS ONE. 2012; 7(12):e51771. doi: 10.1371/journal.pone.0051771 PMID: 23272163
27. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clinical pharmacology and therapeutics. 2001; 69(3):169-74. Epub 2001/03/10. doi: 10.1067/mcp.2001.114164 PMID: 11240981.
28. Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nature medicine. 2012; 18(4):521-8. Epub 2012/03/20. doi: 10.1038/nm.2713 PMID: 22426421.
29. Naik E, O'Reilly LA, Asselin-Labat ML, Merino D, Lin A, Cook M, et al. Destruction of tumor vasculature and abated tumor growth upon VEGF blockade is driven by proapoptotic protein Bim in endothelial cells. The Journal of experimental medicine. 2011; 208(7):1351-8. Epub 2011/06/08. doi: 10.1084/jem. 20100951 PMID: 21646395; PubMed Central PMCID: PMCPMC3135358.
30. Yang F, Jove V, Xin H, Hedvat M, Van Meter TE, Yu H. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Molecular cancer research: MCR. 2010; 8(1):35-45. Epub 2010/01/08. doi: 10.1158/1541-7786.mcr-09-0220 PMID: 20053726; PubMed Central PMCID: PMCPMC2808420.
31. Tan HS, Li H, Hong YW, Toh CK, Wong A, Lopes G, et al. Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore. Clinical genitourinary cancer. 2014. Epub 2014/12/30. doi: 10.1016/j.clgc.2014.11.004 PMID: 25541325.
32. Common Terminology Criteria for Adverse Events Version 3.0: National Cancer Institute; [updated August 9, 2006]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic-Applications/ctc.htm.
33. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer (Oxford, England: 1990). 2009; 45(2):228-47. Epub 2008/12/23. PMID: 19097774.
34. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-Alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20(1):289-96 Epub 2002/01/05. PMID: 11773181.
35. Onizuka M, Kunii N, Toyosaki M, Machida S, Ohgiya D, Ogawa Y, et al. Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients. Bone marrow transplantation. 2011; 46(8):1113-7. Epub 2010/11/26. doi: 10.1038/bmt. 2010.273 PMID: 21102498.
36. Jeannesson E, Albertini L, Siest G, Gomes AM, Ribeiro V, Aslanidis C, et al. Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. Fundamental & clinical pharmacology. 2007; 21(4):411-8. Epub 2007/07/20. doi: 10.1111/j.1472-8206.2007.00507.x PMID: 17635180.
37. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American statistical association. 1958; 53(282):457-81.
38. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer chemotherapy reports Part 1. 1966; 50(3):163-70. Epub 1966/03/01. PMID: 5910392.
39. Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. American journal of epidemiology. 2009; 169(4):505-14. Epub 2009/01/08. doi: 10.1093/aje/kwn359 PMID: 19126586; PubMed Central PMCID: PMCPMC2640163.
40. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for wholegenome association and population-based linkage analyses. Am J Hum Genet. 2007; 81(3):559-75. Epub 2007/08/19. doi: 10.1086/519795 PMID: 17701901; PubMed Central PMCID: PMC1950838.